The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
Open accessAbstract
BACKGROUND: Effective new therapies are needed for rheumatoid arthritis. Current therapies target the products of activated macrophages; however, T cells also have an important role in rheumatoid arthritis. A fusion protein--cytotoxic T-lymphocyte-associated antigen 4-IgG1 (CTLA4Ig)--is the first in a new class of drugs known as costimulation blockers being evaluated for the treatment of rheumatoid arthritis. CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, blocking the engagement of CD28 on T cells and preventing T-cell activation. A preliminary study showed that CTLA4Ig may be effective for the treatment of rheumatoid arthritis. METHODS: We randomly assigned patients with active rheumatoid arthritis despite methotrexate therapy to receive 2 mg of CTLA4Ig per kilogram of body weight (105 patients), 10 mg of CTLA4Ig per kilogram (115 patients), or placebo (119 patients) for six months. All patients also received methotrexate therapy during the study. The clinical response was assessed at six months with use of the criteria of the American College of Rheumatology (ACR), which define the response according to its extent: 20 percent (ACR 20), 50 percent (ACR 50), or 70 percent (ACR 70). Additional end points included measures of the health-related quality of life. RESULTS: Patients treated with 10 mg of CTLA4Ig per kilogram were more likely to have an ACR 20 than were patients who received placebo (60 percent vs. 35 percent, P<0.001). Significantly higher rates of ACR 50 and ACR 70 responses were seen in both CTLA4Ig groups than in the placebo group. The group given 10 mg of CTLA4Ig per kilogram had clinically meaningful and statistically significant improvements in all eight subscales of the Medical Outcomes 36-Item Short-Form General Health Survey. CTLA4Ig was well tolerated, with an overall safety profile similar to that of placebo. CONCLUSIONS: In patients with active rheumatoid arthritis who were receiving methotrexate, treatment with CTLA4Ig significantly improved the signs and symptoms of rheumatoid arthritis and the health-related quality of life. CTLA4Ig is a promising new therapy for rheumatoid arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
(1994) · Medical Entomology and Zoology · Cited by 4,156
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationGregersen, P. K., Silver, J., & Winchester, R. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301102 · Cited by 2,599
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Self-citationA Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Self-citationMaini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Self-citationMueller, D. L., Jenkins, M. K., & Schwartz, R. H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.002305 · Cited by 1,493
Cited by
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Self-citationCTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Human autoimmune diseases: a comprehensive update
Wang, L., Wang, F., & Gershwin, M. E. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12395 · Cited by 1,168
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Self-citationZhang, Q., Dehaini, D., Zhang, Y., Zhou, J., Chen, X., Zhang, L., Fang, R. H., Gao, W., & Zhang, L. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0254-4 · Cited by 958
Effector and Memory CTL Differentiation
Williams, M. A., & Bevan, M. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141548 · Cited by 949
Costimulation Blockade with Belatacept in Renal Transplantation
Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050085 · Cited by 861
Self-citationKlareskog, L., Catrina, A. I., & Paget, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60008-8 · Cited by 787
Larsen, C. P., Pearson, T. C., Adams, A. B., Tso, P., Shirasugi, N., Strobertb, E., Anderson, D., Cowan, S., Price, K., Naemura, J., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00749.x · Cited by 723
Self-citationKremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationNew Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
Synovial fibroblasts: key players in rheumatoid arthritis
Huber, L. C., Distler, O., Tarner, I., Gay, R. E., Gay, S., & Pap, T. (2006) · Rheumatology · doi:10.1093/rheumatology/kel065 · Cited by 607
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Ruperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio-Pérez, N., Silva, C. A., Abud-Mendoza, C., Burgos-Vargas, R., Gerloni, V., Melo-Gomes, J. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60998-8 · Cited by 560
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Self-citationThe TIGIT/CD226 Axis Regulates Human T Cell Function
Lozano, E., Dominguez-Villar, M., Kuchroo, V., & Hafler, D. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103627 · Cited by 476
Toward a better understanding of methotrexate
Kremer, J. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20278 · Cited by 474
Self-citationKremer, J. M., Dougados, M., Emery, P., Durez, P., Sibilia, J., Shergy, W., Steinfeld, S., Tindall, E., Becker, J., Li, T., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21201 · Cited by 444
Self-citationStrategies toward rheumatoid arthritis therapy; the old and the new
Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27860 · Cited by 443
MHC class II proteins and disease: a structural perspective
Jones, E. Y., Fugger, L., Strominger, J. L., & Siebold, C. (2006) · Nature Reviews Immunology · doi:10.1038/nri1805 · Cited by 411
Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Worthy, G., Landewé, R., Smolen, J. S., Emery, P., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126573 · Cited by 406
Self-citationDas, J., Chen, P., Norris, D., Padmanabha, R., Lin, J., Moquin, R. V., Shen, Z., Cook, L. S., Doweyko, A. M., Pitt, S., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060727j · Cited by 397
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40044 · Cited by 394
Self-citationOrgan transplantation—how much of the promise has been realized?
Lechler, R. I., Sykes, M., Thomson, A. W., & Turka, L. A. (2005) · Nature Medicine · doi:10.1038/nm1251 · Cited by 390
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J. C., & Keystone, E. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22070 · Cited by 386
Self-citationTryptophan-kynurenine pathway is dysregulated in inflammation and immune activation
Zou, M.-H. (2015) · Frontiers in Bioscience · doi:10.2741/4363 · Cited by 361
Methotrexate in Rheumatoid Arthritis
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-418 · Cited by 345
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
Sugamura, K., Ishii, N., & Weinberg, A. D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1371 · Cited by 335
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
van der Pouw Kraan, T. C. T. M., Wijbrandts, C. A., van Baarsen, L. G. M., Voskuyl, A. E., Rustenburg, F., Baggen, J. M., Ibrahim, S. M., Fero, M., Dijkmans, B. A. C., Tak, P. P., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.063412 · Cited by 313
Koenders, M. I., Lubberts, E., Oppers-Walgreen, B., van den Bersselaar, L., Helsen, M. M., Di Padova, F. E., Boots, A. M. H., Gram, H., Joosten, L. A. B., & van den Berg, W. B. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62961-6 · Cited by 310
Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
Strehl, C., Ehlers, L., Gaber, T., & Buttgereit, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01744 · Cited by 308
“In this context, it should be noted that blocking co-stimulation targeting CD80/CD86-CD28 interaction significantly improved the signs and symptoms of RA illustrating the importance of T cells in the pathogenesis (91).”
BackgroundRana, A. K., Li, Y., Dang, Q., & Yang, F. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.016 · Cited by 303
Weinblatt, M., Schiff, M., Goldman, A., Kremer, J., Luggen, M., Li, T., Chen, D., & Becker, J.-C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055111 · Cited by 300
Self-citationLopez-Olivo, M. A., Tayar, J. H., Martinez-Lopez, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
Systemic inflammation in heart failure – The whys and wherefores
Yndestad, A., Kristian Damås, J., Øie, E., Ueland, T., Gullestad, L., & Aukrust, P. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9196-2 · Cited by 294
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Furst, D. E. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.10.002 · Cited by 291
Targeting signal transduction as a strategy to treat inflammatory diseases
O'Neill, L. A. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2070 · Cited by 283
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
Treatment of rheumatoid arthritis: state of the art 2009
van Vollenhoven, R. F. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.182 · Cited by 277
Design of effective immunotherapy for human autoimmunity
Feldmann, M., & Steinman, L. (2005) · Nature · doi:10.1038/nature03727 · Cited by 277
Adaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 270
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Essential role of microRNA‐155 in the pathogenesis of autoimmune arthritis in mice
Blüml, S., Bonelli, M., Niederreiter, B., Puchner, A., Mayr, G., Hayer, S., Koenders, M. I., van den Berg, W. B., Smolen, J., & Redlich, K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30281 · Cited by 253
Targeting monocytes/macrophages in the treatment of rheumatoid arthritis
Davignon, J.-L., Hayder, M., Baron, M., Boyer, J.-F., Constantin, A., Apparailly, F., Poupot, R., & Cantagrel, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes304 · Cited by 209
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196
“7] 25%), based on a minimum expected ACR20 response benefit of IV abatacept 25% greater than that of placebo (7,23).”
BackgroundSelf-citationArnold, C. R., Pritz, T., Brunner, S., Knabb, C., Salvenmoser, W., Holzwarth, B., Thedieck, K., & Grubeck-Loebenstein, B. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.01.018 · Cited by 42
Metadata
- Authors
- Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., Williams, G. R., Becker, J.-C., Hagerty, D. T., & Moreland, L. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-13
- Volume
- 349
- Issue
- 20
- Pages
- 1907-1915
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014081699
- Cited by
- 1,058
- References
- 38
- FWCI
- 53.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.